Assessing AML-based risk criteria in patients with accelerated/blast-phase MPN treated with less-intensive therapy

Overview of attention for article published in Blood Advances, May 2025

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (83rd percentile)
Good Attention Score compared to outputs of the same age and source (70th percentile)

Mentioned by

twitter: 9 X users

bluesky: 4 Bluesky users

Readers on

mendeley: 5 Mendeley

So far, Altmetric has seen 7 Bluesky posts from 4 Bluesky users, with an upper bound of 906 followers.

Day 11 - risk stratification in patients with MPN-AP/BP getting lower-intensity therapies pubmed.ncbi.nlm.nih.gov/39969200/

Day 11 - AML-based risk stratification in MPN-AP/BP treated with lower-intensity therapy pubmed.ncbi.nlm.nih.gov/39969200/

Featured today by @MSKLibrary: Assessing AML-based risk criteria in patients with accelerated/blast-phase MPN treated with less-intensive therapy dx.doi.org/10.1182/bloo... #MPNResearch #AMLInsights #LeukemiaResearch #RiskStratification #LessIntensive…

Check out the final version of our @bloodjournals.hematology.org Blood Advances manuscript on applying ELN AML risk stratification to patients with MPN-AP/BP treated with lower-intensity therapies! ashpublications.org/bloodadvance...

This page shows the most recent Bluesky posts that mention this research output. Click here to find out how to access more activity, including 3 additional Bluesky posts.